Your provider can weigh these predispositions alongside clinical assessment to guide compound selection
Both amylin- and GLP-1-based pharmacotherapies have been separately examined preclinically in the context of combinatorial therapies for obesity treatment with other hormonal systems ( e
For those with diabetes, monitoring should include blood glucose checks as clinically indicated and hemoglobin A1c reassessment approximately 3 months after therapy changes, per American Diabetes Association guidelines
Most patients receive their medication within a few days of approval
Costs vary widely based on insurance, diagnosis, pharmacy, location, manufacturer programs, and whether the medication is being prescribed for diabetes or weight management
Effect of one weeks treatment with a GLP-1R Agonist on glycemia and HGP Diabetes, 53:1187;2004 Postprandial metabolism in T2DM with and without DPP-4 inhibition K Azuma, JCEM 2008 Islet cell response to hypoglycemia with and without DPP-4 inhibition Glucagon Vlda 47 ng/L Cntl 34 ng/L ISR Vlda -70 pmol/m2/min Cntl -62 pmol/m2/min PP Vlda 115 pmol/L Cntl 62 pmol/L B Ahren, JCEM 2009 Treatment with Exenatide does not impair the counterregulatory glucagon response Diabetes 53:2397;2004
